ライフサイエンスコーパス: Bacillus anthracis

1 ences the expression of virulence factors in Bacillus anthracis.

2 W rabbits exposed to aerosols of Ames strain Bacillus anthracis.

3 ion of spores of Bacillus species, including Bacillus anthracis.

4 not the same species as, Bacillus cereus and Bacillus anthracis.

5 thrax is caused by the sporulating bacterium Bacillus anthracis.

6 boxylic acid) (DPA), which is a biomarker of Bacillus anthracis.

7 assessment of potential therapeutics against Bacillus anthracis.

8 - and capsule-encoding virulence plasmids of Bacillus anthracis.

9 es, designated ltaS1 to -4, in the genome of Bacillus anthracis.

10 nases Bas2152 (PrkD) and Bas2037 (PrkG) from Bacillus anthracis.

11 om the human pathogen and bioterrorism agent Bacillus anthracis.

12 s expression of the major virulence genes of Bacillus anthracis.

13 x using recombinant protective Ag (rPA) from Bacillus anthracis.

14 a serine/threonine kinase (STK) expressed by Bacillus anthracis.

15 i, a spore forming nonpathogenic simulant of Bacillus anthracis.

16 sufficient to protect against infection with Bacillus anthracis.

17 ), serine/threonine kinase (BA-Stk1) pair in Bacillus anthracis.

18 by the Gram-positive spore-forming bacterium Bacillus anthracis.

19 or the virulence of the pathogenic bacterium Bacillus anthracis.

20 haired HRS/J mice are extremely resistant to Bacillus anthracis.

21 racteristics of recombinant DNA primase from Bacillus anthracis.

22 by the gram-positive spore-forming bacterium Bacillus anthracis.

23 sented by another deadly bacterial pathogen, Bacillus anthracis.

24 L11 exhibit antimicrobial activities against Bacillus anthracis.

25 at infections caused by the biodefense agent Bacillus anthracis.

26 ulator of plasmid-encoded virulence genes in Bacillus anthracis.

27 n or putative polysaccharide deacetylases of Bacillus anthracis.

28 positive pathogens Staphylococcus aureus and Bacillus anthracis.

29 y the spore-forming, gram-positive bacterium Bacillus anthracis.

30 athogenic bacilli Listeria monocytogenes and Bacillus anthracis.

31 ne and/or during disseminated infection with Bacillus anthracis.

32 ne responses of wild herbivore hosts against Bacillus anthracis.

33 agent of the disease anthrax is the spore of Bacillus anthracis.

34 i-phagocytic capsule conferring virulence on Bacillus anthracis.

35 conditions, similar to previous findings in Bacillus anthracis.

36 contribute to infections by bacteria such as Bacillus anthracis.

37 , including 5 strains of Yersinia pestis and Bacillus anthracis.

38 Wip1, a tectivirus that infects the pathogen Bacillus anthracis.

39 elements (29 nt), a fluoride riboswitch from Bacillus anthracis(48 nt), and a frame-shifting element

40 racellular vesicles from the supernatants of Bacillus anthracis, a Gram-positive bacillus that is a p

41 Bacillus anthracis, a Gram-positive pathogen, produces S

42 Bacillus anthracis, a spore-forming bacterium, is such a

43 uring advanced stages of inhalation anthrax, Bacillus anthracis accumulates at high levels in the blo

44 We also provide evidence that the S-layer of Bacillus anthracis acts as a molecular sieve that is chi

45 These plasmids are analogous to the Bacillus anthracis Ames plasmids pXO1 and pXO2 that enco

46 rmining the median lethal dose (LD50) of the Bacillus anthracis Ames strain in guinea pigs and invest

47 dentify key genetic features of the letters' Bacillus anthracis Ames strain.

48 y diverse panel of inbred mice and spores of Bacillus anthracis Ames, we investigated host susceptibi

49 ema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality

50 toxin (LT) is a critical virulence factor of Bacillus anthracis and an important means by which this

51 ed to pathogenic Bacillus species, including Bacillus anthracis and Bacillus thuringiensis.

52 -C pathogens: Category A priority pathogens; Bacillus anthracis and Clostridium botulinum, and Catego

53 community relevant spore-forming pathogens, Bacillus anthracis and Clostridium difficile.

54 o exhibit epitope diversity, and epitopes of Bacillus anthracis and Clostridium tetani toxins, as the

55 A bibliometric analysis of the Bacillus anthracis and Ebola virus archival literature w

56 Therefore, the abilities of Bacillus anthracis and Escherichia coli gyrase and topoi

57 Interactions between spores of Bacillus anthracis and macrophages are critical for the

58 efficient transfer of ICEBs1 into and out of Bacillus anthracis and that cwlT was needed for ICEBs1 t

59 M by analyzing the nine-strain pan-genome of Bacillus anthracis and up to 62 strains of Escherichia c

60 of growth inhibition against F. tularensis , Bacillus anthracis , and Staphylococcus aureus .

61 tivity against MRSA, Listeria monocytogenes, Bacillus anthracis, and a vancomycin-resistant Enterococ

62 t oxidative stress in Staphylococcus aureus, Bacillus anthracis, and Bacillus subtilis.

63 genes is presented from sequenced B. cereus, Bacillus anthracis, and Bacillus thuringiensis strains.

64 from the culture medium of Bacillus cereus, Bacillus anthracis, and Bacillus thuringiensis when stra

65 res of the Bacillus cereus group (B. cereus, Bacillus anthracis, and Bacillus thuringiensis) are surr

66 ry sites of YpeB cleavage were identified in Bacillus anthracis, and it was shown that the stable pro

67 cterial species, including Escherichia coli, Bacillus anthracis, and Streptococcus pneumoniae, studie

68 tor, and edema factor, the protein toxins of Bacillus anthracis , are among its most important virule

69 e of the pathogens Clostridium difficile and Bacillus anthracis, are uniquely stable cell forms, high

70 tective antigen (PA83) of anthrax toxin from Bacillus anthracis as a foreign antigen and expressed PA

71 due to the pathogenic exotoxins produced by Bacillus anthracis as well as other virulence factors of

72 Rapid presymptomatic diagnosis of Bacillus anthracis at early stages of infection plays a

73 inations of polystyrene beads, gram-positive Bacillus anthracis, B. thuringiensis, and B. atrophaeus

74 simple method was developed for detection of Bacillus anthracis (BA) endospores and for differentiati

75 tency against Staphylococcus aureus (Sa) and Bacillus anthracis (Ba) helicases.

76 ally, primates infected with toxin-secreting Bacillus anthracis bacilli developed a rapid and marked

77 strains of the Bacillus cereus group, i.e., Bacillus anthracis, Bacillus cereus, Bacillus mycoides,

78 analogues, bind dihydrofolate reductase from Bacillus anthracis (BaDHFR) with lower affinity than is

79 protein product of one such gene, MccF from Bacillus anthracis (BaMccF), is able to cleave intact an

80 The P4H from Bacillus anthracis (BaP4H) has been postulated to act on

81 The lung is the terminal target of Bacillus anthracis before death, whatever the route of i

82 uctures of BLIP-II alone and in complex with Bacillus anthracis Bla1 beta-lactamase revealed no signi

83 PB and HPB carrying ARGs in the manures were Bacillus anthracis, Bordetella pertussis, and B. anthrac

84 uccessfully implemented for the detection of Bacillus anthracis, botulinum B, and tularemia in comple

85 btilis and other Bacillus species, including Bacillus anthracis, bound rabbit IgM through an unconven

86 tive antibody (Ab)-mediated immunity against Bacillus anthracis but has limited efficacy and duration

87 ins play a major role in the pathogenesis of Bacillus anthracis by subverting the host defenses.

88 ee binary bacterial toxins: anthrax toxin of Bacillus anthracis, C2 toxin of Clostridium botulinum, a

89 exes with different classes of inhibitors of Bacillus anthracis, Campylobacter jejuni, and Clostridiu

90 Bacillus anthracis can cause inhalational anthrax.

91 potential biological warfare agents, such as Bacillus anthracis, causal agent of anthrax in humans an

92 The endospore forming bacterium Bacillus anthracis causes lethal anthrax disease in huma

93 er, these methods rely on recovery of viable Bacillus anthracis cells from swabs of cutaneous lesions

94 nt compounds in vivo protecting mice against Bacillus anthracis challenge.

95 ystal structure at 2.10 A resolution for the Bacillus anthracis coenzyme A-disulfide reductase isofor

96 Germination is a key step for successful Bacillus anthracis colonization and systemic disseminati

97 toxin (LT) is an A-B type toxin secreted by Bacillus anthracis, consisting of the cellular binding m

98 The Gram-positive pathogen Bacillus anthracis contains 24 genes whose products harb

99 Bacillus anthracis contains two megaplasmids, pXO1 and p

100 Insertional mutagenesis of exsM in Bacillus anthracis DeltaSterne resulted in a partial sec

101 ing, synthetic, and structural studies using Bacillus anthracis DHPS.

102 ng glycans on spores, whereas others such as Bacillus anthracis do not.

103 is a tripartite virulence factor produced by Bacillus anthracis during infection.

104 The production of cAMP from Bacillus anthracis edema toxin (ET) activates gene expre

105 Bacillus anthracis edema toxin (ET) consists of protecti

106 Bacillus anthracis elaborates a poly-gamma-d-glutamic ac

107 The envelope of Bacillus anthracis encompasses a proteinaceous S-layer w

108 e active in vitro against bacterial forms of Bacillus anthracis encountered in vivo, as well as in vi

109 The Bacillus anthracis endospore loses resistance properties

110 solution that the active form of DAPDC from Bacillus anthracis, Escherichia coli, Mycobacterium tube

111 Bacillus anthracis exhibits a rapid growth rate during s

112 hal concentrations of the anthrax bacterium, Bacillus anthracis, for grazing animals in a natural sys

113 Bacillus anthracis forms metabolically dormant endospore

114 or off-label broad-spectrum efficacy against Bacillus anthracis; Francisella tularensis; Coxiella bur

115 d adenosine synthesis also enabled escape of Bacillus anthracis from phagocytic clearance.

116 anthrax by facilitating the dissemination of Bacillus anthracis from the lung in early disease and pr

117 Anthrax toxin, a major virulence factor of Bacillus anthracis, gains entry into target cells by bin

118 e GSLEs that have been shown to be active in Bacillus anthracis germination: sleB, cwlJ1, and cwlJ2.

119 Here we demonstrate by NMR that the Bacillus anthracis glmS riboswitch selectively binds the

120 Bacillus anthracis grows in chains of rod-shaped cells,

121 The Gram-positive pathogen Bacillus anthracis grows in characteristic chains of ind

122 Bacillus anthracis has four GSLEs: CwlJ1, CwlJ2, SleB, a

123 Bacillus anthracis has four putative GSLEs, based upon s

124 These results suggest that Bacillus anthracis has the ability to evade the host's i

125 m the secondary cell wall polysaccharides of Bacillus anthracis, has been chemically synthesized.

126 of Staphylococcus aureus and petrobactin of Bacillus anthracis hold considerable potential as a sing

127 nce identity with anthrax lethal factor from Bacillus anthracis; however, we have shown that the toxi

128 have determined three crystal structures of Bacillus anthracis IMPDH, in a phosphate ion-bound (term

129 T cells that recognize the protective Ag of Bacillus anthracis in both anthrax vaccine-adsorbed vacc

130 The lung is the site of entry for Bacillus anthracis in inhalation anthrax, the deadliest

131 B. subtilis vesicles, but also vesicles from Bacillus anthracis, indicating a mechanism that crossed

132 identified several compounds that protected Bacillus anthracis infected macrophages from cell death.

133 termine if Nod1/Nod2 are involved in sensing Bacillus anthracis infection and eliciting protective im

134 t observations derived from animal models of Bacillus anthracis infection are inconsistent with aspec

135 ly shown to have increased susceptibility to Bacillus anthracis infection relative to wild-type anima

136 pears to be important in the pathogenesis of Bacillus anthracis infection, but its causes are unclear

137 estigated the effect of alpha-GalCer against Bacillus anthracis infection, the agent of anthrax.

138 he most prevalent form of naturally acquired Bacillus anthracis infection, which is associated with e

139 mortality rates associated with inhalational Bacillus anthracis infection.

140 Bacillus anthracis is a bioterrorism agent classified by

141 Bacillus anthracis is a Gram-positive spore-forming bact

142 The antiphagocytic capsule of Bacillus anthracis is a major virulence factor.

143 Bacillus anthracis is a spore-forming, Gram-positive pat

144 Bacillus anthracis is a sporulating Gram-positive bacter

145 Bacillus anthracis is a tier 1 select agent with the pot

146 The lethal factor (LF) enzyme secreted by Bacillus anthracis is a zinc hydrolase that is chiefly r

147 Inhalational anthrax caused by Bacillus anthracis is associated with high mortality pri

148 Pathogenesis of Bacillus anthracis is associated with the production of

149 The anthrax edema toxin (ET) of Bacillus anthracis is composed of the receptor-binding c

150 The exosporium of Bacillus anthracis is comprised of two distinct layers:

151 The virulence of Bacillus anthracis is critically dependent on the cytoto

152 r illustrated by the demonstration that once Bacillus anthracis is engineered to express high levels

153 The arginase from Bacillus anthracis is not well characterized; therefore,

154 poly gamma-D-glutamic acid (gammaDPGA) from Bacillus anthracis is presented.

155 perspective, the glmS ribozyme derived from Bacillus anthracis is the best characterized.

156 Bacillus anthracis is the causative agent of anthrax in

157 Bacillus anthracis is the causative agent of anthrax, an

158 Bacillus anthracis is the causative agent of anthrax, wh

159 Bacillus anthracis is the causative agent of anthrax.

160 ne of the two essential virulence factors of Bacillus anthracis is the poly-gamma-D-glutamic acid (ga

161 ver, the role of lipoprotein biosynthesis in Bacillus anthracis is unknown.

162 ction of cytokine responses and induction of Bacillus anthracis lethal factor (LF)-specific adaptive

163 bed to initiate the inflammasome response to Bacillus anthracis lethal factor.

164 The Bacillus anthracis lethal toxin (LT) has been shown to a

165 inflammasome was identified as the sensor of Bacillus anthracis lethal toxin (LT) in mouse macrophage

166 protective antigen and lethal factor of the Bacillus anthracis lethal toxin using semiconductor quan

167 ation of NLRP1 by various stimuli, including Bacillus anthracis lethal toxin, Toxoplasma gondii, mura

168 an alveolar epithelial cells are a target of Bacillus anthracis lethal toxin.

169 immune response to other virulence factors (Bacillus anthracis LF and EF) than HLA-homozygous subjec

170 ral important rod-shaped pathogens including Bacillus anthracis, Listeria monocytogenes, and Clostrid

171 Interestingly, the Bacillus anthracis lrgAB mutant displayed decreased stat

172 Here we report the crystal structures of Bacillus anthracis NadD in complex with three NadD inhib

173 m-negative, including Staphylococcus aureus, Bacillus anthracis, Neisseria gonorrhoeae, and Neisseria

174 of the manganese-tyrosyl radical cofactor of Bacillus anthracis NrdF and the redox properties of B. a

175 Escherichia coli, Staphylococcus aureus, and Bacillus anthracis particles.

176 Spore germination is the first step to Bacillus anthracis pathogenicity.

177 Here, we describe the capacity of Bacillus anthracis peptidoglycan (BaPGN) to trigger an a

178 The lethal toxin (LeTx) of Bacillus anthracis plays a central role in the pathogene

179 x stems from the shielding properties of the Bacillus anthracis poly-gamma-d-glutamic acid capsule.

180 Bacillus anthracis produces virulence toxins required fo

181 The etiologic agent of inhalational anthrax, Bacillus anthracis, produces virulence toxins that are i

182 Bacillus anthracis proliferates to high levels within ve

183 ted that a linear determinant in domain 2 of Bacillus anthracis protective Ag (PA) is a potentially i

184 have shown that intranasal coapplication of Bacillus anthracis protective Ag (PA) together with a B.

185 with GalXM conjugated to a protein carrier, Bacillus anthracis protective Ag.

186 tion between the human CMG2 receptor and the Bacillus anthracis protective antigen (PA) is essential

187 y using Lactobacillus acidophilus to deliver Bacillus anthracis protective antigen (PA) via specific

188 idually disease enhancing or neutralizing to Bacillus anthracis protective antigen (PA), a component

189 large polypeptide segments derived from the Bacillus anthracis protective antigen (PA).

190 sent study, using a plasmid that encodes the Bacillus anthracis protective antigen (PA63) gene fragme

191 diverse GC responses to two complex antigens-Bacillus anthracis protective antigen and influenza hema

192 Using ovalbumin and Bacillus anthracis protective antigen protein as model a

193 Single channels of Bacillus anthracis protective antigen, PA(63), were reco

194 we generated IgG2a and IgG2b variants of the Bacillus anthracis protective antigen-binding IgG1 monoc

195 in (Atx), a key virulence factor secreted by Bacillus anthracis, provides a robust biophysical model

196 , or 3-mercaptopyruvate sulfurtransferase in Bacillus anthracis, Pseudomonas aeruginosa, Staphylococc

197 mini-pXO1 plasmid containing a replicon from Bacillus anthracis pXO1 (181.6 kb) was identified by mak

198 Bacillus anthracis pXO1 minireplicon (MR) plasmid consis

199 Bacillus anthracis remains a serious bioterrorism concer

200 toxins produced by Clostridium botulinum and Bacillus anthracis represents a particularly challenging

201 Pathogenesis by Bacillus anthracis requires coordination between two dis

202 Bacillus anthracis secretes two bipartite toxins, edema

203 Bacillus anthracis secretes two virulence factors: a tri

204 The Bacillus anthracis secretome includes protective antigen

205 Bacillus anthracis shares many regulatory loci with the

206 ctrochemical genosensor for the detection of Bacillus anthracis, specific towards the regulatory gene

207 The outermost layer of the Bacillus anthracis spore consists of an exosporium compr

208 The outermost layer of the Bacillus anthracis spore consists of an exosporium compr

209 :1 ratio to toxin and protected mice against Bacillus anthracis spore infection.

210 The Bacillus anthracis spore is the causative agent of the d

211 The sdAb-A5 binds BclA, a Bacillus anthracis spore protein, with high affinity (K(

212 omponent of complement, and a portion of the Bacillus anthracis spore surface protein BclA, all of wh

213 The outermost layer of the Bacillus anthracis spore, the exosporium, is composed of

214 Bacillus anthracis spores are enclosed by an exosporium

215 Bacillus anthracis spores are the etiologic agent of ant

216 Ingestion of Bacillus anthracis spores causes gastrointestinal (GI) a

217 Pulmonary exposure to Bacillus anthracis spores initiates inhalational anthrax

218 the interaction between macrophage cells and Bacillus anthracis spores is of significant importance w

219 Nutrient-dependent germination of Bacillus anthracis spores is stimulated when receptors l

220 Bacillus anthracis spores, the etiological agents of ant

221 etrocyclin-1 protects mice from infection by Bacillus anthracis spores.

222 alational anthrax is caused by inhalation of Bacillus anthracis spores.

223 , we demonstrate that PHB deficiency impairs Bacillus anthracis sporulation through diminishing the e

224 ied as a novel low-molecular weight thiol in Bacillus anthracis, Staphylococcus aureus, and several o

225 tors of several bacterial toxins produced by Bacillus anthracis, Staphylococcus aureus, Clostridium p

226 Colonies of Bacillus anthracis Sterne allow the growth of papillatio

227 and T cell-mediated immune responses against Bacillus anthracis Sterne challenge.

228 for adhesion of the anthrax vaccine strain, Bacillus anthracis Sterne, to host cells.

229 In Bacillus anthracis str. Sterne, resistance to oxidative

230 The susceptibility of most Bacillus anthracis strains to beta-lactam antibiotics is

231 Transcription of the Bacillus anthracis structural genes for the anthrax toxi

232 During high-impact events involving Bacillus anthracis, such as the Amerithrax incident of 2

233 harbors S-layer genes, including homologs of Bacillus anthracis surface array protein (Sap), extracta

234 (ET) is one of two binary toxins produced by Bacillus anthracis that contributes to the virulence of

235 for the development of improved vaccines for Bacillus anthracis that increase not only neutralizing A

236 Anthrax is caused by strains of Bacillus anthracis that produce two key virulence factor

237 the events associated with the emergence of Bacillus anthracis the causative agent of anthrax-a leth

238 In Bacillus anthracis the siderophore petrobactin is vital

239 Bacillus anthracis, the anthrax agent, is a member of th

240 irus, the etiological agent of smallpox, and Bacillus anthracis, the bacterial pathogen responsible f

241 e culture, shows significant activity toward Bacillus anthracis, the bacterial pathogen responsible f

242 Bacillus anthracis, the causative agent of anthrax and a

243 Bacillus anthracis, the causative agent of anthrax disea

244 Spores of Bacillus anthracis, the causative agent of anthrax, are

245 Infection with Bacillus anthracis, the causative agent of anthrax, can

246 we discover that the gram-positive bacterium Bacillus anthracis, the causative agent of anthrax, does

247 Bacillus anthracis, the causative agent of anthrax, form

248 Bacillus anthracis, the causative agent of anthrax, is a

249 Bacillus anthracis, the causative agent of anthrax, is a

250 Bacillus anthracis, the causative agent of anthrax, is p

251 Bacillus anthracis, the causative agent of anthrax, reli

252 Bacillus anthracis, the causative agent of anthrax, repl

253 Bacillus anthracis, the causative agent of anthrax, requ

254 A surface adhesin of Bacillus anthracis, the causative agent of anthrax, requ

255 In Bacillus anthracis, the causative agent of anthrax, tran

256 Bacillus anthracis, the causative agent of anthrax, util

257 We report the 1.40 A structure of a P4H from Bacillus anthracis, the causative agent of anthrax, whos

258 derophore, is required for full virulence of Bacillus anthracis, the causative agent of anthrax.

259 ria that has hitherto not been identified in Bacillus anthracis, the causative agent of anthrax.

260 activity against the Gram-positive bacterium Bacillus anthracis, the causative agent of anthrax.

261 ific bactericidal activity toward strains of Bacillus anthracis, the causative agent of anthrax.

262 Bacillus anthracis, the causative agent of the disease a

263 operties of metallo-beta-lactamase Bla2 from Bacillus anthracis, the enzyme was overexpressed, purifi

264 sterol-dependent cytolysin (CDC) secreted by Bacillus anthracis, the etiologic agent for anthrax.

265 Bacillus anthracis, the etiological agent of anthrax dis

266 ysis of a systemic bacterial infection using Bacillus anthracis, the etiological agent of anthrax dis

267 Here, we report that the peptidoglycan of Bacillus anthracis, the etiological agent of anthrax, is

268 Bacillus anthracis, the etiological agent of anthrax, is

269 Bacillus anthracis, the etiological agent of anthrax, is

270 In Bacillus cereus and its close relative Bacillus anthracis, the major pilin protein BcpA is clea

271 In common with Bacillus subtilis and Bacillus anthracis, the presence of anhydromuropeptides

272 In Bacillus anthracis, the siderophore petrobactin is requi

273 The key genes required for Bacillus anthracis to cause anthrax have been acquired r

274 se anthrax lethal factor (LF) is secreted by Bacillus anthracis to promote disease virulence through

275 , GrlA(E85A), GrlA(S81F/E85A) and GrlA(S81F) Bacillus anthracis topoisomerase IV, their sensitivity t

276 macrophages, the lethal factor component of Bacillus anthracis toxin binds to a carrier protein (PA)

277 dies (MAbs) have been reported for the other Bacillus anthracis toxin components, but relatively few

278 that HNP-1 to HNP-3 inhibit lethal toxin of Bacillus anthracis, toxin B of Clostridium difficile, di

279 The protective antigen component of Bacillus anthracis toxins can interact with at least thr

280 bs) are potential therapeutic agents against Bacillus anthracis toxins, since there is no current tre

281 We sampled the Bacillus anthracis transcriptome under a variety of grow

282 h under iron limitation, Bacillus cereus and Bacillus anthracis, two human pathogens from the Bacillu

283 In order to better characterize the Bacillus anthracis typing phage AP50c, we designed a gen

284 The pathogen Bacillus anthracis uses the Sortase A (SrtA) enzyme to a

285 The current Bacillus anthracis vaccine consists largely of protectiv

286 es were considered the primary target of the Bacillus anthracis virulence factor lethal toxin because

287 Edema toxin (ET) is one of the major Bacillus anthracis virulence factors and consists of the

288 The Bacillus anthracis virulence regulator AtxA controls tra

289 s of its target, the protective antigen from Bacillus anthracis We show how rational design based on

290 Using virulent and nonvirulent strains of Bacillus anthracis, we have shown that secretion of ATP

291 a potential role for NK cells in immunity to Bacillus anthracis, we utilized primary human and murine

292 the CcpA homologues of Bacillus subtilis and Bacillus anthracis were not affected by the Stk1 ortholo

293 bioterrorism agents like Yersinia pestis and Bacillus anthracis which feature on the Center for Disea

294 is initiated by endospores of the bacterium Bacillus anthracis, which are introduced into the lung.

295 threatening disease caused by infection with Bacillus anthracis, which expresses lethal factor and th

296 premature termination of hasA translation in Bacillus anthracis, which is known to escape phagocytic

297 known to confer ciprofloxacin resistance in Bacillus anthracis, Yersinia pestis, and Francisella tul

298 Forty-six distinct strains of Bacillus anthracis, Yersinia pestis, Francisella tularen

299 er water or nucleic acids from BT organisms (Bacillus anthracis, Yersinia pestis, Francisella tularen

300 elease of bacterial biothreat agents such as Bacillus anthracis, Yersinia pestis, or Burkholderia pse